

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 March 2020 (26.03.2020)



(10) International Publication Number
WO 2020/057540 A8

(51) International Patent Classification:

C07K 16/24 (2006.01) *A61K 39/395* (2006.01)
C12N 5/10 (2006.01) *A61P 37/00* (2006.01)
C12N 15/13 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2019/106409

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

(22) International Filing Date:

18 September 2019 (18.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/106158

18 September 2018 (18.09.2018) CN

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

23 July 2020 (23.07.2020)

(71) Applicant (for CN only): **I-MAB BIOPHARMA CO., LTD.** [CN/CN]; Room 802, 8F, 1 Bld., West Tower, 88 Shangke Road, Pudong New Area, Shanghai 201210 (CN).

(15) Information about Correction:

see Notice of 23 July 2020 (23.07.2020)

(71) Applicant (for all designated States except CN): **I-MAB BIOPHARMA US LIMITED** [US/US]; 9801 Washington Blvd, Suite 710, Gaithersburg, MD 20878 (US).

(72) Inventors: **GU, Haijuan**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). **YANG, Qiumei**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN).

(74) Agent: **SHANGHAI BESHINING LAW OFFICE**; 21st Floor SFECO Mansion, 681 Xiaomujiao Road, Shanghai 200032 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER

(57) Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.